Revolutionary Breakthrough: FDA Approves First Drug to Treat Pulmonary Embolism Directly

Sotatracept, the first drug in the world to treat pulmonary embolism itself, has been approved by the American Food and Drug Administration (FDA) after a decade of no developments in the treatment of the disease. This breakthrough drug offers significant advancements to patients who have not found balance with existing treatments.

Pulmonary embolism is a serious disease that primarily affects young people, especially women, with the peak incidence occurring between the ages of 30-40. Patients are categorized based on function levels and risk levels ranging from 1 (highest) to 4 (lowest). The new drug sotatracept has a unique mechanism of action that inhibits the component “activin,” changing the mechanism of cells driving the disease.

The Ministry of Health typically approves drugs that have passed FDA approval after receiving research findings from the company. This breakthrough drug offers improvements beyond existing treatments, improving survival rates, delaying disease progression, and reducing the risk of worsening disease or death by approximately 84%.

Prof. Mordechai Kramer, director of the pulmonary department at Blinson Hospital, says “Pulmonary hypertension is a serious disease with a significant risk to life.” The new drug brings significant advancements to patients who have not found balance with existing treatments.